Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of “Hold” by Brokerages

Entrada Therapeutics, Inc. (NASDAQ:TRDA) has been given an average recommendation of “Hold” by the five analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $18.50.

Several equities research analysts have recently commented on TRDA shares. Roth Mkm set a $13.00 target price on Entrada Therapeutics in a report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a report on Monday, December 29th. Guggenheim set a $20.00 price objective on shares of Entrada Therapeutics and gave the stock a “buy” rating in a research report on Tuesday. Finally, Oppenheimer initiated coverage on shares of Entrada Therapeutics in a research note on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 target price for the company.

Entrada Therapeutics Trading Up 2.6%

NASDAQ TRDA traded up $0.27 on Tuesday, hitting $10.82. 210,898 shares of the stock traded hands, compared to its average volume of 245,044. The company has a market capitalization of $413.53 million, a P/E ratio of -4.35 and a beta of -0.12. Entrada Therapeutics has a twelve month low of $4.93 and a twelve month high of $13.82. The stock has a 50-day moving average of $10.73 and a 200 day moving average of $7.95.

Insider Buying and Selling at Entrada Therapeutics

In other Entrada Therapeutics news, CFO Kory James Wentworth sold 8,910 shares of the company’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $9.98, for a total transaction of $88,921.80. Following the sale, the chief financial officer owned 110,026 shares of the company’s stock, valued at approximately $1,098,059.48. This represents a 7.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Bros. Advisors Lp Baker purchased 100,736 shares of Entrada Therapeutics stock in a transaction that occurred on Wednesday, November 12th. The stock was acquired at an average cost of $7.76 per share, with a total value of $781,711.36. Following the transaction, the insider owned 4,664,924 shares in the company, valued at $36,199,810.24. This trade represents a 2.21% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold 408,910 shares of company stock worth $3,608,922 over the last quarter. Company insiders own 7.59% of the company’s stock.

Institutional Investors Weigh In On Entrada Therapeutics

Institutional investors have recently made changes to their positions in the stock. AlphaQuest LLC lifted its holdings in shares of Entrada Therapeutics by 239.8% during the 2nd quarter. AlphaQuest LLC now owns 39,625 shares of the company’s stock valued at $266,000 after buying an additional 27,963 shares during the period. Corton Capital Inc. bought a new stake in shares of Entrada Therapeutics in the 2nd quarter valued at approximately $193,000. Los Angeles Capital Management LLC grew its holdings in Entrada Therapeutics by 60.6% during the 2nd quarter. Los Angeles Capital Management LLC now owns 44,632 shares of the company’s stock valued at $300,000 after purchasing an additional 16,840 shares during the last quarter. Geode Capital Management LLC grew its stake in Entrada Therapeutics by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock worth $4,245,000 after acquiring an additional 42,479 shares in the last quarter. Finally, Intech Investment Management LLC lifted its holdings in Entrada Therapeutics by 15.7% during the second quarter. Intech Investment Management LLC now owns 17,702 shares of the company’s stock worth $119,000 after buying an additional 2,397 shares during the period. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.